Aditi Shastri, MBBS, Albert Einstein College of Medicine, New York City, NY, comments on the results of a study that showed synergy between pyrimethamine and venetoclax in pre-clinical models of hypomethylating agent (HMA)-resistant myelodysplastic syndromes (MDS). This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.